Glycoconjugate Journal

, Volume 18, Issue 11–12, pp 931–942 | Cite as

MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment

  • Pinku Mukherjee
  • Amelia R. Ginardi
  • Cathy S. Madsen
  • Teresa L. Tinder
  • Fred Jacobs
  • Joanne Parker
  • Babita Agrawal
  • B. Michael Longenecker
  • Sandra J. Gendler


Pancreatic cancer is a highly aggressive, treatment refractory disease and is the fourth leading cause of death in the United States. In humans, 90% of pancreatic adenocarcinomas over-express altered forms of a tumor-associated antigen, MUC1 (an epithelial mucin glycoprotein), which is a target for immunotherapy. Using a clinically relevant mouse model of pancreas cancer that demonstrates peripheral and central tolerance to human MUC1 and develops spontaneous tumors of the pancreas, we have previously reported the presence of functionally active, low affinity, MUC1-specific precursor cytotoxic T cells (pCTLs). Hypothesis for this study is that MUC1-based immunization may enhance the low level MUC1-specific immunity that may lead to an effective anti-tumor response. Data demonstrate that MUC1 peptide-based immunization elicits mature MUC1-specific CTLs in the peripheral lymphoid organs. The mature CTLs secrete IFN-γ and are cytolytic against MUC1-expressing tumor cells in vitro. However, active CTLs that infiltrate the pancreas tumor microenvironment become cytolytically anergic and are tolerized to MUC1 antigen, allowing the tumor to grow. We demonstrate that the CTL tolerance could be reversed at least in vitro with the use of anti-CD40 co-stimulation. The pancreas tumor cells secrete immunosuppressive cytokines, including IL-10 and TGF-ß that are partly responsible for the down-regulation of CTL activity. In addition, they down-regulate their MHC class I molecules to avoid immune recognition. CD4+CD25+ T regulatory cells, which secrete IL-10, were also found in the tumor environment. Together these data indicate the use of several immune evasion mechanisms by tumor cells to evade CTL killing. Thus altering the tumor microenvironment to make it more conducive to CTL killing may be key in developing a successful anti-cancer immunotherapy.

CTL antigens/peptides/epitopes tolerance tumor immunity transgenic models 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Greenlee RT, Murray T, Bolden S, Wingo PA, Cancer statistics, CA Cancer J 50, 7–33 (2000).Google Scholar
  2. 2.
    Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ, Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model, Cancer Res 58, 315–21 (1998).Google Scholar
  3. 3.
    Mukherjee P, Ginardi AR, Madsen CS, Sterner CJ, Adriance MC, Tevethia MJ, Gendler SJ, Mice with spontaneous pancreatic cancer naturally develop MUC1-specific CTLs that eradicate tumors when adoptively transferred, J Immunol 165, 3451–60 (2000).Google Scholar
  4. 4.
    Mukherjee P, Ginardi AR, Tinder TL, Sterner CJ, Gendler SJ, MUC1-specific CTLs eradicate tumors when adoptively transferred in vivo, Clin Can Res 7, 848s–55s (2001).Google Scholar
  5. 5.
    Ridge JP, Fuchs EJ, Matzinger P, Neonatal tolerance revisited: Turning on newborn T cells with dendritic cells, Science 271, 1723–6 (1996).Google Scholar
  6. 6.
    Sikut R, Sikut A, Zhang K, Baeckstrom D, Hansson GC, Reactivity of antibodies with highly glycosylated MUC1 mucins from colon carcinoma cells and bile, In Tumor Biology, edited by Rye PD, Price MR (S. Karger Medical and Scientific Publishers, 1998), pp. 122–6.Google Scholar
  7. 7.
    Papac RJ, Spontaneous regression of cancer, Cancer Treat Rev 22, 395–423 (1996).Google Scholar
  8. 8.
    Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, et al., Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma, Nat Med 4, 321–7 (1998).Google Scholar
  9. 9.
    Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles S, Connors M, Steinberg SM, Rosenberg SA, Marincola FM, Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression, J Immunol 163, 6292–300 (1999).Google Scholar
  10. 10.
    Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, et al., Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3, Int J Cancer 63, 883–5 (1995).Google Scholar
  11. 11.
    Monsurro V, Nielsen MB, Perez-Diez A, Dudley ME, Wang E, Rosenberg SA, Marincola FM, Kinetics of TCR use in response to repeated epitope-specific immunization, J Immunol 166, 5817–25 (2001).Google Scholar
  12. 12.
    Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, King A, Ogg GS, Spiegel HM, Conlon C, Spina CA, et al., HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function, J Exp Med 192, 63–75 (2000).Google Scholar
  13. 13.
    Gamadia LE, Rentenaar RJ, Baars PA, Remmerswaal EB, Surachno S, Weel JF, Toebes M, Schumacher TN, ten Berge IJ, van Lier RA, Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers, Blood 98, 754–61 (2001).Google Scholar
  14. 14.
    Hamann D, Kostense S, Wolthers KC, Otto SA, Baars PA, Miedema F, van Lier RA, Evidence that human CD8+CD45RA+CD27-cells are induced by antigen and evolve through extensive rounds of division, Int Immunol 11, 1027–33 (1999).Google Scholar
  15. 15.
    Nagai M, Kubota R, Greten TF, Schneck JP, Leist TP, Jacobson S, Increased activated humanTcell lymphotropic virus type I (HTLV-1) Tax11-19-specific memory and effector CD8+ cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: Correlation with HTLV-I provirus load, J Infect Dis 183, 197–205 (2001).Google Scholar
  16. 16.
    Reilly RT, Gottlieb MB, Ercolini AM, Machiels JP, Kane CE, Okoye FI, Muller WJ, Dixon KH, Jaffee EM, HER-2/neu is a 942 Mukherjee et al. tumor rejection target in tolerized HER-2/neu transgenic mice, Cancer Res 60, 3569–76 (2000).Google Scholar
  17. 17.
    Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, LeiRY, Weintraub D, Jaffee EM, The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors, Cancer Res 61, 880–3 (2001).Google Scholar
  18. 18.
    Nukina M, Mochida Y, Sakaguchi S, Sakaguchi G, Purification of Clostridium botulinum type G progenitor toxin, Zentralbl Bakteriol Mikrobiol Hyg [A] 268, 220–7 (1988).Google Scholar
  19. 19.
    Papiernik M, de Moraes ML, Pontoux C, Vasseur F, Penit C, Regulatory CD4 T cells: Expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency, Int Immunol 10, 371–8 (1998).Google Scholar
  20. 20.
    Read S, Mauze S, Asseman C, Bean A, Coffman R, Powrie F, CD38+CD45RB(low) CD4+T cells:Apopulation of T cells with immune regulatory activities in vitro, Eur J Immunol 28, 3435–47 (1998).Google Scholar
  21. 21.
    Smith H, Sakamoto Y, Kasai K, Tung KS, Effector and regulatory cells in autoimmune oophoritis elicited by neonatal thymectomy, J Immunol 147, 2928–33 (1991).Google Scholar
  22. 22.
    Suri-Payer E, Amar AZ, Thornton AM, Shevach EM, CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells, J Immunol 160, 1212–8 (1998).Google Scholar
  23. 23.
    van Stipdonk MJ, Lemmens EE, Schoenberger SP, Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation, Nat Immunol 2, 423–9 (2001).Google Scholar
  24. 24.
    Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR, Induction of a CD8+ cytotoxic T lymphocyte response by crosspriming requires cognate CD4+T cell help, J Exp Med 186, 65–70 (1997).Google Scholar
  25. 25.
    Husmann LA, Bevan MJ, Cooperation between helper T cells and cytotoxic T lymphocyte precursors, Ann NY Acad Sci 532, 158–69 (1988).Google Scholar
  26. 26.
    Akiba H, Oshima H, Takeda K, Atsuta M, Nakano H, Nakajima A, Nohara C, Yagita H, Okumura K, CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells, J Immunol 162, 7058–66 (1999).Google Scholar
  27. 27.
    Bansal-Pakala P, Jember AG, Croft M, Signaling through OX40 (CD134) breaks peripheral T-cell tolerance, Nat Med 7, 907–12 (2001).Google Scholar
  28. 28.
    Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR, Help for cytotoxic-T-cell responses is mediated by CD40 signalling, Nature 393, 478–80 (1998).Google Scholar
  29. 29.
    Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, Croft M, The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion, J Immunol 165, 3043–50 (2000).Google Scholar
  30. 30.
    Gramaglia I, Weinberg AD, Lemon M, Croft M, Ox-40 ligand: A potent costimulatory molecule for sustaining primary CD4 T cell responses, J Immunol 161, 6510–7 (1998).Google Scholar
  31. 31.
    Maxwell JR, Weinberg A, Prell RA, Vella AT, Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion, J Immunol 164, 107–12 (2000).Google Scholar
  32. 32.
    Tevethia MJ, Bonneau RH, Griffith JW, Mylin L, A simian virus 40 large T-antigen segment containing amino acids 1 to 127 and expressed under the control of the rat elastase-1 promoter produces pancreatic acinar carcinomas in transgenic mice, J Virol 71, 8157–66 (1997).Google Scholar
  33. 33.
    Silver LM, Laboratory mice, In Mouse Genetics Concepts and Applications (Oxford University Press, 1995), pp. 32–61.Google Scholar
  34. 34.
    Price MR, Rye PD, Petrakou E, Murray A, Brady K, Imai S, Haga S, Kiyozuka Y, Schol D, Meulenbroek MF, et al., Summary report on the ISOBM TD-4 Workshop: Analysis of 56 monoclonal antibodies against the MUC1 mucin (San Diego, California, 1996) Tumour Biol 19, 1–20 (1998).Google Scholar
  35. 35.
    Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM, Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor, J Exp Med 176, 1693–702 (1992).Google Scholar
  36. 36.
    Guan HH, Budzynski W, Koganty RR, Krantz MJ, Reddish MA, Rogers JA, Longenecker BM, Samuel J, Liposomal formulations of synthetic MUC1 peptides: Effects of encapsulation versus surface display of peptides on immune responses, Bioconjug Chem 9, 451–8 (1998).Google Scholar
  37. 37.
    Boni LT, Batenjany MM, Neville ME, Guo Y, Xu L, Wu F, Mason JT, Robb RJ, Popescu MC, Interleukin-2-induced small unilamellar vesicle coalescence, Biochim Biophys Acta 1514, 127–38 (2001).Google Scholar
  38. 38.
    Maeda H, Tsuru S, Shiraishi A, Improvement of macrophage dysfunction by administration of anti-transforming growth factor-beta antibody in EL4-bearing hosts, Jpn J Cancer Res 85, 1137–43 (1994).Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Pinku Mukherjee
    • 1
  • Amelia R. Ginardi
    • 1
  • Cathy S. Madsen
    • 1
  • Teresa L. Tinder
    • 1
  • Fred Jacobs
    • 2
  • Joanne Parker
    • 2
  • Babita Agrawal
    • 2
  • B. Michael Longenecker
    • 2
  • Sandra J. Gendler
    • 3
  1. 1.Department of Biochemistry and Molecular BiologyMayo Clinic ScottsdaleScottsdaleUSA
  2. 2.Biomira, Inc.EdmontonCanada
  3. 3.Department of Biochemistry and Molecular BiologyMayo Clinic ScottsdaleScottsdaleUSA

Personalised recommendations